Orexo AB listed on Stockholm Stock Exchange

As of today Orexo AB, a drug delivery company, is traded on Stockholm Stock Exchange’s O List.

Orexo develops proprietary, patented pharmaceuticals by refining existing pharmaceutical substances. The company has commercialized one product, three product candidates are in the clinical phase - where of one is out-licensed in North America and Japan – and two product candidates are in the formulation development phase. The company’s net sales during the first nine months of 2005 totaled SEK 59 million. “Orexo regards its listing on the Stockholm Stock Exchange as an important strategic step in its efforts to support the company’s future development and strengthen its financial position. We warmly welcome Orexo to the Exchange and wish the company every success in its continued efforts, now with the support provided by the listing”, says Jenny Rosberg, President of Cash Market Sweden, OMX. Photos from the welcoming ceremony and a filmed interview with Orexo’s President and Chief Executive Officer Zsolt Lavotha will be available on the Stockholm Stock Exchange website, www.omxgroup.com/stockholmstockexchange, under Corporate actions and Changes in listed companies/Listings. Orexo will be traded in the Health Care sector. Further information about Orexos industry classification and similar matters is available on www.omxgroup.com/stockholmsborsen under Press and Exchange notices /Search /Equity related information.